tert-butyl 4-[(1-methyl-1H-imidazol-2-yl)methyl]piperazine-1-carboxylate | 942950-58-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl 4-[(1-methyl-1H-imidazol-2-yl)methyl]piperazine-1-carboxylate
• 英文别名: tert-Butyl 4-((1-methyl-1H-imidazol-2-yl)methyl)piperazine-1-carboxylate；tert-butyl 4-[(1-methylimidazol-2-yl)methyl]piperazine-1-carboxylate
• CAS: 942950-58-5
• 化学式: C₁₄H₂₄N₄O₂
• mdl: MFCD24392190
• 分子量: 280.37
• InChiKey: BJBQFPQDTKYKEH-UHFFFAOYSA-N

物化性质

• 沸点：
  413.7±40.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.714
• 拓扑面积：
  50.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-[(1-methyl-1H-imidazol-2-yl)methyl]piperazine-1-carboxylate 在 盐酸 、 碳酸氢钠 作用下， 以 乙醇 、 N,N-二甲基乙酰胺 为溶剂， 反应 8.0h， 生成 (S)-5-fluoro-2-(6-fluoroimidazo[1,2-a]pyridin-3-yl)-N-(1-(5-fluoropyridin-2-yl)ethyl)-6-(4-((1-methyl-1H-imidazol-2-yl)methyl)piperazin-1-yl)pyrimidin-4-amine
  参考文献：
  名称：

  [EN] IMIDAZOLOPYRIMIDIN-2-YL DERIVATIVES AS JAK INHIBITORS
  [FR] DÉRIVÉS D'IMIDAZOPYRIDMIN-2-YL COMME INHIBITEURS DE LA JAK

  摘要：

  新的咪唑吡啶-2-基衍生物已被披露；以及它们的制备方法，包含它们的药物组合物以及它们作为Janus激酶（JAK）抑制剂用于治疗骨髓增生性疾病、白血病、淋巴瘤恶性肿瘤、骨髓和器官移植排斥反应、免疫介导性疾病和炎症性疾病的用途。

  公开号：

  WO2015091531A1
• 作为产物：
  描述：

  2-(氯甲基)-1-甲基-1H-咪唑盐酸盐 、 N-Boc-哌嗪 在 三乙胺 作用下， 以 乙腈 为溶剂， 反应 24.0h， 以74%的产率得到tert-butyl 4-[(1-methyl-1H-imidazol-2-yl)methyl]piperazine-1-carboxylate
  参考文献：
  名称：

  [EN] PYRAZOLOPYRIMIDIN-2-YL DERIVATIVES AS JAK INHIBITORS
  [FR] DÉRIVÉS DE PYRAZOLOPYRIMIDIN-2-YLE UTILISÉS COMME INHIBITEURS DE JAK

  摘要：

  新的吡唑吡啶-2-基衍生物被披露；以及它们的制备方法，包含它们的药物组合物以及它们作为Janus激酶（JAK）抑制剂在治疗中的用途。

  公开号：

  WO2015086693A1

文献信息

• Enzyme Inhibitors
  申请人：Bavetsias Vassilios

  公开号：US20090247507A1

  公开（公告）日：2009-10-01

  Compounds of formula (I), are aurora kinase inhibitors: wherein X is —N—, —CH2—N—, —CH2—CH—, or —CH—; R1 is a radical of formula (IA) wherein Z is —CH2—, —NH—, -0-, —S(O)— —S—, —S(O)2 or a divalent monocyclic carbocyclic or heterocyclic radical having 3-7 ring atoms; Alk is an optionally substituted divalent C1-C6 alkylene radical; A is hydrogen or an optionally substituted monocyclic carbocyclic or heterocyclic ring having 5-7 ring atoms; r, s and t are independently 0 or 1, provided that when A is hydrogen then at least one of r and s is 1; R2 is halogen, —CN, —CF3, —OCH3, or cyclopropyl; and R3 is a radical of formula (IB) wherein Q is hydrogen or an optionally substituted phenyl or monocyclic heterocyclic ring with 5 or 6 ring atoms; Z&It;1> is —S—, —S(O)—, —S(O)2—, —O—, —SO2NH—, —NHSO2—, NHC(═O)NH, —NH(C═S)NH—, Or —N(R4)—wherein R4 is hydrogen, C1-C3 alkyl, cycloalkyl, or benzyl; and Alk&It;1> and Alk&It;2> are, independently, optionally substituted divalent C1-C3 alkylene radicals; and m, n and p are independently 0 or 1. Data supplied from the esp@cenet datatbase—Worldwide d77

  式(I)的化合物是极光激酶抑制剂：其中X是—N—、—CH2—N—、—CH2—CH—或—CH—；R1是式(IA)的基团，其中Z是—CH2—、—NH—、-O-、—S(O)—、—S—、—S(O)2或具有3-7个环原子的二价单环碳环或杂环基团；Alk是任选取代的二价C1-C6亚烷基基团；A是氢或任选取代的具有5-7个环原子的单环碳环或杂环环；r、s和t独立地为0或1，前提是当A为氢时，至少一个r和s为1；R2是卤素、—CN、—CF3、—OCH3或环丙基；R3是式(IB)的基团，其中Q是氢或任选取代的苯基或具有5或6个环原子的单环杂环环；Z<1>是—S—、—S(O)—、—S(O)2—、—O—、—SO2NH—、—NHSO2—、NHC(═O)NH、—NH(C═S)NH—或—N(R4)—，其中R4是氢、C1-C3烷基、环烷基或苄基；Alk<1>和Alk<2>独立地是任选取代的二价C1-C3亚烷基基团；m、n和p独立地为0或1。数据来自esp@cenet数据库—Worldwide d77。
• Enzyme inhibitors
  申请人：Cancer Research Technology Limited

  公开号：US08088761B2

  公开（公告）日：2012-01-03

  Compounds of formula (I), are aurora kinase inhibitors: wherein X is —N—, —CH2-N—, —CH2-CH—, or —CH—; R1 is a radical of formula (IA) wherein Z is —CH2-, —NH—, -0-, —S(O)— —S—, —S(O)2 or a divalent monocyclic carbocyclic or heterocyclic radical having 3-7 ring atoms; Alk is an optionally substituted divalent C1-C6 alkylene radical; A is hydrogen or an optionally substituted monocyclic carbocyclic or heterocyclic ring having 5-7 ring atoms; r, s and t are independently 0 or 1, provided that when A is hydrogen then at least one of r and s is 1; R2 is halogen, —CN, —CF3, —OCH3, or cyclopropyl; and R3 is a radical of formula (IB) wherein Q is hydrogen or an optionally substituted phenyl or monocyclic heterocyclic ring with 5 or 6 ring atoms; Z&It;1> is —S—, —S(O)—, —S(O)2-, —O—, —SO2NH—, —NHSO2-, NHC(═O)NH, —NH(C═S)NH—, Or —N(R4)— wherein R4 is hydrogen, C1-C3 alkyl, cycloalkyl, or benzyl; and Alk&It;1> and Alk&It;2> are, independently, optionally substituted divalent C1-C3 alkylene radicals; and m, n and p are independently 0 or 1.

  式（I）的化合物是极光激酶抑制剂：其中X是- N-，- CH2-N-，- CH2-CH-或- CH-；R1是式（IA）的基团，其中Z是- CH2-，- NH-，- 0-，- S（O）-，- S-，- S（O）2或具有3-7个环原子的二价单环芳环或杂环基团；Alk是可选取代的二价C1-C6烷基链基团；A是氢或具有5-7个环原子的可选取代的单环芳环或杂环；r，s和t独立地为0或1，前提是当A为氢时，至少有一个r和s为1；R2是卤素，- CN，- CF3，- OCH3或环丙基；R3是式（IB）的基团，其中Q是氢或可选取代的具有5或6个环原子的苯基或单环杂环；Z1是- S-，- S（O）-，- S（O）2-，- O-，- SO2NH-，- NHSO2-，NHC（=O）NH，- NH（C= S）NH-或- N（R4）-，其中R4是氢，C1-C3烷基，环烷基或苯甲基；Alk1和Alk2是独立的可选取代的二价C1-C3烷基链基团；m，n和p独立地为0或1。
• Imidazo[4,5-<i>b</i>]pyridine Derivatives As Inhibitors of Aurora Kinases: Lead Optimization Studies toward the Identification of an Orally Bioavailable Preclinical Development Candidate
  作者：Vassilios Bavetsias、Jonathan M. Large、Chongbo Sun、Nathalie Bouloc、Magda Kosmopoulou、Mizio Matteucci、Nicola E. Wilsher、Vanessa Martins、Jóhannes Reynisson、Butrus Atrash、Amir Faisal、Frederique Urban、Melanie Valenti、Alexis de Haven Brandon、Gary Box、Florence I. Raynaud、Paul Workman、Suzanne A. Eccles、Richard Bayliss、Julian Blagg、Spiros Linardopoulos、Edward McDonald

  DOI：10.1021/jm100262j

  日期：2010.7.22

  Lead optimization studies using 7 as the starting point led to a new class of imidazo[4,5-b]pyridine-based inhibitors of Aurora kinases that possessed the 1-benzylpiperazinyl motif at the 7-position, and displayed favorable in vitro properties. Cocrystallization of Aurora-A with 40c (CCT137444) provided a clear understanding into the interactions of this novel class of inhibitors with the Aurora kinases. Subsequent physicochemical property refinement by the incorporation of solubilizing groups led to the identification of 3-((4-(6-bromo-2-(4-(4-methylpiperazin-1-yl)phenyl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)methyl)-5-methylisoxazole (51, CCT137690) which is a potent inhibitor of Aurora kinases (Aurora-A IC(50) = 0.015 +/- 0.003 muM, Aurora-B IC(50) = 0.025 muM, Aurora-C IC(50) = 0.019 muM). Compound 51 is highly orally bioavailable, and in in vivo efficacy studies it inhibited the growth of SW620 colon carcinoma xenografts following oral administration with no observed toxicities as defined by body weight loss.
• ENZYME INHIBITORS
  申请人：Cancer Research Technology Limited

  公开号：EP1963315B1

  公开（公告）日：2014-10-08
• US8088761B2
  申请人：——

  公开号：US8088761B2

  公开（公告）日：2012-01-03